Adial Pharmaceuticals EBITDA 2017-2024 | ADIL

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Adial Pharmaceuticals ebitda from 2017 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Adial Pharmaceuticals ebitda from 2017 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$178.8B
Regeneron Pharmaceuticals (REGN)	$126.4B
Vertex Pharmaceuticals (VRTX)	$124.2B
Gilead Sciences (GILD)	$103.4B
Bristol Myers Squibb (BMY)	$100.3B
CSL (CSLLY)	$97.4B
GSK (GSK)	$88.2B
Alnylam Pharmaceuticals (ALNY)	$35.2B
Argenex SE (ARGX)	$31.2B
BioNTech SE (BNTX)	$29.7B
Biogen (BIIB)	$28.9B
Moderna (MRNA)	$27.7B
Illumina (ILMN)	$20.7B
BeiGene (BGNE)	$19.2B
Genmab (GMAB)	$17.5B
BioMarin Pharmaceutical (BMRN)	$13.4B
Vaxcyte (PCVX)	$13B
Incyte (INCY)	$12.8B
Insmed (INSM)	$12.6B
Exact Sciences (EXAS)	$12.6B
Sarepta Therapeutics (SRPT)	$12B
Bio-Techne Corp (TECH)	$11.9B
QIAGEN (QGEN)	$10.4B
Legend Biotech (LEGN)	$9.3B
Bio-Rad Laboratories (BIO.B)	$9.1B
Roivant Sciences (ROIV)	$8.9B
Ascendis Pharma (ASND)	$8.5B
Intra-Cellular Therapies (ITCI)	$7.9B
Exelixis (EXEL)	$7.9B
Halozyme Therapeutics (HALO)	$7.8B